Introduction
============

Benefit--risk assessment is a key component of the regulation of medicines and subsequent medical treatment decisions ([@R17]; [@R18]; [@R19]; [@R24]; [@R25], [@R26]). The assessment and communication of benefit--risk analysis is fundamentally important during drug development so as to identify the value of new products for public health and to better enable individual treatment decisions. Numerous regulatory and industry initiatives to standardize approaches to carrying out and communicating benefit--risk assessment are in development ([@R4]; [@R1]; [@R18]; [@R25], [@R26], [@R27]; [@R7]; [@R10]; [@R21]). One of the more commonly used methods is the Benefit--Risk Action Team (BRAT) framework ([@R1]; [@R18]; [@R23]; [@R9]). This framework, developed by a multidisciplinary team sponsored by the Pharmaceutical Research and Manufacturers of America, provides a structured approach to benefit--risk assessment that addresses the practical complexities of real-world assessments.

Long-term maintenance therapy in schizophrenia is an important clinical and public health concern that requires a careful risk--benefit balance. Defining this balance for individuals with schizophrenia is complex because multiple efficacy and safety endpoints must be simultaneously considered. In addition, actual and perceived impact of therapy varies from patient to patient, and head-to-head treatment-comparison data are difficult to obtain. As a result, benefit--risk assessment for long-acting injectable (LAI) versus oral antipsychotics is of special interest because their differing adherence and pharmacokinetic profiles address other important clinical dimensions ([@R12]; [@R13], [@R14]). LAIs are increasingly valued for their ability to simplify dosing schedules, allow clinicians to monitor adherence, and potentially reduce the chance of noncompliance that can be associated with oral antipsychotics ([@R28]). However, head-to-head trials comparing LAIs with their oral alternatives are limited.

In prior work, we conducted a comparative-effectiveness analysis of paliperidone palmitate once-monthly (PP1M) and oral extended-release (ER) paliperidone for the maintenance treatment of schizophrenia in adults during ∼1 year of treatment ([@R20]). Using similar methods for each outcome, this current post-hoc analysis applied the BRAT framework to provide a benefit--risk comparison of LAI (PP1M) and oral ER formulations of paliperidone in the maintenance treatment of schizophrenia in adults.

Methods
=======

BRAT framework
--------------

The BRAT framework is a structured approach to pharmaceutical benefit--risk assessment that facilitates the selection, organization, summarization, and communication of evidence relevant to benefit--risk decisions ([@R1]; [@R18]; [@R23]). It was chosen for the current analysis because the complexity and number of endpoints considered for this assessment required more focus on assessment setup, data selection, and endpoint definitions than on quantitative modeling ([@R6]; [@R9]). The approach and endpoints used here are similar to that of a recent application of the BRAT framework to LAI antipsychotics ([@R2]).

Source data
-----------

In the absence of head-to-head trials, we analyzed patient-level, long-term efficacy and safety data from the double-blind (DB) maintenance phase of two similar randomized, DB, placebo-controlled, schizophrenia relapse-prevention studies of paliperidone ER (NCT00086320) ([@R15]) and PP1M (NCT00111189) ([@R8]). Both of the original studies were approved by the institutional review board at each site and were carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients. The nearly identical, four-phase designs (i.e. run-in/transition, stabilization, DB, and an optional open-label extension) of these two studies allowed for a statistical comparison of results. Inclusion, exclusion, stabilization, and relapse criteria were comparable between the two studies ([@R15]; [@R8]). Other sources of data were considered for this comparative work, including meta-analyses of relapse studies in the literature. None were pursued, however, because of widely varying patient inclusion criteria and differences in endpoint definitions, particularly variations in the definitions and measurement of relapse.

In both the [@R15] and [@R8] studies, once patients were stabilized, they were randomly assigned to the DB phase and continued active treatment or received matching placebo until relapse, withdrawal from the study, or study completion. Both studies were terminated early on the basis of a preplanned interim analysis (Table [1](#T1){ref-type="table"}). At the time the studies were stopped, 91 patients in the paliperidone ER study (35 in the run-in phase and 56 in the stabilization phase) and 76 patients in the PP1M study (all in the stabilization phase) were considered to have completed the study according to protocol. The two studies had similar but slightly different criteria for determining stabilization. To match the randomization criterion across studies for this comparative analysis, 25 patients were excluded from the PP1M study because they did not meet the more stringent measures of both the Positive and Negative Syndrome Scale (PANSS) score of up to 70 and the Clinical Global Impression--Severity (CGI-S) score of up to 4 (i.e. not ill to moderately ill) that were used as stabilization criteria in the paliperidone ER study. The end result was 104 patients on paliperidone ER and 193 patients on PP1M in the double-blind phase for this analysis (Table [1](#T1){ref-type="table"}).
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Disposition of patients in paliperidone ER and PP1M studies^a^
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Selection of benefit and risk outcomes
--------------------------------------

Key benefits and risks associated with atypical antipsychotics were identified from the literature, package inserts (i.e. the expected safety events), and consultation with clinical experts. These outcomes are shown in the value tree in Fig. [1](#F1){ref-type="fig"}, a hierarchical depiction of outcomes important for characterizing possible schizophrenia treatments. Precise definitions are shown in Table [2](#T2){ref-type="table"}. The goal was to include all outcomes needed to conduct a benefit--risk assessment.

![Value tree for benefit--risk assessment of atypical antipsychotics for the treatment of schizophrenia. Maintenance of symptom improvement is assessed with both Positive and Negative Syndrome Scale and Clinical Global Impression--Severity outcomes. Extrapyramidal symptoms were assessed using anticholinergics and extrapyramidal symptom--related adverse events. Lipid abnormalities and hyperglycemia were assessed with total cholesterol/high-density lipoprotein and fasting plasma glucose, respectively. AEs, adverse events; CNS, central nervous system; QT, measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle.](yic-31-315-g002){#F1}
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Definitions of efficacy and safety outcomes
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Benefit outcomes included maintenance of symptom improvement measured by both core schizophrenia symptoms (assessed by the PANSS) and clinician judgment of the patient's symptoms (assessed by the CGI-S), relapse (both time to relapse and proportion relapsed), patient functioning \[using the Personal and Social Performance (PSP) scale\], and psychiatric hospitalization (Table [2](#T2){ref-type="table"}). The final set of safety outcomes assessed was selected based on data availability and overall impact of the event (i.e. frequency plus clinical consequences). Stroke and syncope were not included because they had very low incidence; stroke was also considered by the authors as a potential rather than an identified endpoint ([@R3]) for schizophrenia populations, and those at high risk for stroke were excluded from the two studies. Hyperprolactinemia was not included because the majority of patients with elevated prolactin levels had no prolactin-related adverse events and because neither of the studies provided results of serum prolactin to the investigators to avoid unintentional unblinding. Sexual functioning endpoints were not included because neither study included these measures other than as spontaneously reported events.

Definition of outcomes
----------------------

All efficacy endpoints were defined so as to identify loss in stability during the DB maintenance phase after patients had been stabilized (Table [2](#T2){ref-type="table"}). To simultaneously interpret large numbers of endpoints, continuous efficacy endpoints were collapsed into dichotomous variables. Time to relapse (days) was also compared. Thresholds for dichotomization were set according to a clinically meaningful worsening of an event, such as the percentage of patients who had a decrease in PSP score from more than 70 at baseline to 70 or less at endpoint ([@R22]; [@R5]). Patients with events that met this threshold at any point following baseline were considered to have worsened, even if the patient reverted to normal values later in the study.

Statistical methods
-------------------

Because most outcome events occurred at greater frequency at the start of the DB maintenance phase, the analysis was carried out at both 8 and 40 weeks from DB baseline. The 8-week measure was chosen to mitigate the high withdrawal rate in schizophrenia studies. Forty weeks was chosen as a consistent long-term follow-up period for both studies because neither had a predetermined follow-up time and almost no event for any outcome occurred after 40 weeks. All patients who entered the double-blind phases and had efficacy data as of study termination are included in both the 8-week and 40-week analyses, irrespective of whether they completed, withdrew, or relapsed within the double-blind phases. If a patient had at least one event from Table [2](#T2){ref-type="table"} while still in the double-blind phase, that event contributed toward the corresponding endpoint.

The standard approach for an indirect comparison of two therapies accounts for some differences between trials by placebo adjustments of the outcome measures. However, as noted by [@R20], the median time to first relapse in the placebo group of the PP1M study was longer than that for the placebo group of the paliperidone ER study \[paliperidone ER/paliperidone palmitate (PP) hazard ratio (HR), 2.25; 95% confidence interval (CI), 1.59--3.18; *P*\<0.0001\]. Other endpoints also showed differential effects for their respective placebo groups. This is likely because the PP1M formulation used in the stabilization phase remained in plasma for several months \[median apparent half-life (*t*~½~)=25--49 days, depending on dose\], whereas the oral formulation cleared from plasma in a few days (median *t*~½~=23 h). Placebo-corrected comparisons are therefore not meaningful because of the marked differences in pharmacokinetics between the formulations. For this reason, the active arms were compared directly using patient-level data as described by [@R20]. This approach is justified because of the similarity of design and baseline patient characteristics between the trials.

For dichotomous endpoints, the mean (95% CI) risk differences between PP1M and paliperidone ER per 1000 patients (PP minus ER) were calculated over the periods 0 to 8 weeks and 0 to 40 weeks. Results are scaled to this hypothetical population so as to better reflect the benefits and risk on a population level. This risk difference can be interpreted as the additional number of patients from this hypothetical population who would experience an event of interest when treated with PP1M compared with paliperidone ER. A negative value indicates that fewer events occur in the population treated with PP1M and a positive value indicates that fewer events occurred with paliperidone ER; 95% CIs were intended to show statistical differences. When the 95% CI does not include 0, the difference was considered statistically significant. No adjustments were made for multiplicity. For time to relapse, HRs and 95% CIs were assessed using a Cox proportional hazards model.

Results
=======

Baseline demographic and clinical characteristics of the two study populations were comparable and have been reported previously ([@R20]). Briefly, the mean patient age at diagnosis was similar in the PP1M and paliperidone ER treatment arms (26.3 and 27.1 years, respectively), as were baseline PANSS total scores (mean 50.8 and 51.0, respectively) and the mean number of previous hospitalizations for psychosis (2.6 and 2.9, respectively) ([@R20]). The proportions of patients who were mildly ill (47.7 and 47.1%, respectively) or moderately ill (10.9 and 10.6%, respectively), according to CGI-S scores, were also similar ([@R20]).

In 1000 patients treated for 8 weeks with PP1M versus paliperidone ER, there would be 165 (95% CI, 93--237) fewer PSP worsening events for PP1M, 115 (95% CI, 30--199) fewer relapses, 85 (95% CI, 22--147) fewer PANSS worsening events, and 53 (95% CI, 7--98) fewer hospitalization events (Fig. [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). No significant difference was identified for CGI-S worsening, with 32 (95% CI, --12 to 77) fewer events for PP1M. PANSS worsening and CGI-S worsening were both highly correlated with relapse, according to the definition of relapse and the correlation between CGI-S and PANSS ([@R16]). Time to relapse also strongly favors PP1M with an HR of 5.38 (95% CI, 2.21--13.12). In contrast, all harms assessed showed no statistical difference between treatments; all 95% CIs included 0 (Table [3](#T3){ref-type="table"} and Fig. [2](#F2){ref-type="fig"}). No QT interval prolongation, fasting plasma glucose, or total cholesterol/high-density lipoprotein events occurred in either group during weeks 0 to 8.

![Risk differences (per 1000 patients) for key benefit--risk endpoints from 0 to 8 weeks (PP1M vs. paliperidone ER). Diamonds and the adjacent numbers show the point estimates; horizontal bars show 95% confidence intervals. Dark gray bars indicate the efficacy endpoints. Light gray bars indicate the safety endpoints. QT interval prolongation, fasting plasma glucose, and total cholesterol/high-density lipoprotein are not shown because no events occurred in either group. AE, adverse event; CGI-S, Clinical Global Impression--Severity; CI, confidence interval; EPS, extrapyramidal symptom; ER, extended release; PANSS, Positive and Negative Syndrome Scale; PP1M, paliperidone palmitate once-monthly; PSP, Personal and Social Performance.](yic-31-315-g004){#F2}
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Treatment arm and treatment differences for key endpoints from 0 to 8 weeks (PP1M vs. paliperidone ER)
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For treatment over a 40-week period for 1000 patients, there would be 140 (95% CI, 55--225) fewer PSP worsening events for PP1M (Fig. [3](#F3){ref-type="fig"} and Table [4](#T4){ref-type="table"}). Collectively, all other benefits evaluated showed a numerical advantage for PP1M treatment; 95% CIs included 0 and were not statistically significant (Fig. [3](#F3){ref-type="fig"}). Time to relapse strongly favored PP1M, with an HR of 2.52 (95% CI, 1.46--4.35) compared with paliperidone ER ([@R20]). Safety outcomes were not different between treatments. No QT interval prolongation events occurred in either group during weeks 0 to 40.

![Risk differences (per 1000 patients) for key benefit--risk endpoints from 0 to 40 weeks (PP1M vs. paliperidone ER). Diamonds and the adjacent numbers show the point estimates; horizontal bars show 95% confidence intervals. Dark gray bars indicate the efficacy endpoints. Light gray bars indicate the safety endpoints. QT interval prolongation is not shown because no events occurred in either group. AE, adverse event; CGI-S, Clinical Global Impression--Severity; CI, confidence interval; EPS, extrapyramidal symptom; ER, extended release; FPG, fasting plasma glucose; PANSS, Positive and Negative Syndrome Scale; PP1M, paliperidone palmitate once-monthly; PSP, Personal and Social Performance; QT, measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle; TC/HDL ratio, total cholesterol/high-density lipoprotein ratio.](yic-31-315-g006){#F3}
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Treatment arm and treatment differences for key endpoints from 0 to 40 weeks (PP1M vs. paliperidone ER)
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Injection-site reaction pain was moderate in 1% of patients during the double-blind phase of the PP1M study (no cases were severe) and no injection-site reactions had moderate or severe redness, swelling, or induration (data not shown). Using the units of Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, in 1000 patients, 10 would experience moderate injection-site reaction pain with paliperidone palmitate, whereas of course none would experience such pain with oral paliperidone ER.

An additional consideration for benefit--risk assessment is the impact of formulation on adherence. Although results from the two clinical trials do not provide information on adherence in real-world use and the preplanned early terminations of both studies further complicates interpretation, the duration of exposure and withdrawal rates provide some indication of the degree to which patients choose to stay in the trials. The median (range) duration of exposure in the DB phases was 170 days (1--407 days) for PP1M versus 45 days (3--330 days) for paliperidone ER. Withdrawal rates were 15% for PP1M and 19% for paliperidone ER (Table [1](#T1){ref-type="table"}). Both measurements suggest that adherence on PP1M is greater than adherence on paliperidone ER.

Discussion
==========

Despite the paucity of clinical trial data directly comparing the oral and 1-month injectable formulations of paliperidone, a comparative effectiveness analysis and the BRAT framework enabled comparisons of benefits and risks across two similarly conducted clinical trials. The results of this post-hoc benefit--risk analysis support the value of PP1M therapy in long-term schizophrenia treatment. This benefit manifests much more in the first 8 weeks of treatment than at 40 weeks; however, differential withdrawal between the PP1M and paliperidone ER arms may have shifted results to favor paliperidone ER as the studies progressed. Data suggest a benefit for PP1M versus paliperidone ER when used as maintenance treatment in stable patients with schizophrenia. There were fewer functioning (PSP) and symptomatic (PANSS) worsening events, and fewer relapses and hospitalizations in early treatment, with the benefit for fewer PSP events continuing throughout at least 40 weeks. The safety risk profile for the long-acting nature of PP appeared similar to that of paliperidone ER over the period studied, although 1% of PP1M patients experienced moderate pain at the injection site.

The analysis has several limitations, many of which are addressed in the comparative effectiveness analysis on which this work is partly based ([@R20]). Both studies were stopped early as a result of significant benefit of the active treatment arms over placebo; thus, the median duration of exposure in the DB phases of the studies was markedly different (171 days for the PP1M study and 44 days for the paliperidone ER study), making equivalent long-term comparisons impossible. The combined run-in/transition/stabilization phases were 33 weeks for the PP1M study versus 14 weeks for the paliperidone ER study. The dose range in the paliperidone ER study was 3--15 mg/day (mean dose 10.8). This includes doses above the currently approved range (3--12 mg/day). In contrast, the allowable dose range in the PP1M study was 39--156 mg (mean dose 82.8). This equates to roughly 2--8 mg/day (mean dose 4.2) of paliperidone ER and is narrower than the approved range of 39--234 mg ([@R11]). Potentially, the lower dose equivalent used with PP1M could have shifted safety to favor PP1M and shifted efficacy to favor paliperidone ER. The dose difference is in good part due to trial design and the requirement to establish a loading dose. These challenges were addressed, where possible, with analytic adjustments to the patient-level data, including alignment of stabilization criteria, development of binary categorical variables, and use of two discrete time periods for analysis. Placebo correction could not be accurately conducted because concentrations were measurable in the plasma for several months for the LAI group versus several days for the oral group after withdrawal from active treatment in the DB phase. A direct comparison would be required to confirm the results of this analysis. Although most patients remained in both trials at 8 weeks, differences in outcomes observed between observations at weeks 8 and 40 can be challenging to interpret because of missing data and the possibility that the observed 'missingness' was not randomly distributed across treatment arms. In particular, because the PP1M study active arm retained a greater percentage of patients after 8 weeks than did the paliperidone ER study, the only changes possible in the rate differences between 8 and 40 weeks are additional events for PP1M, potentially pushing the rate differences toward favoring paliperidone ER for both benefit and harm items. This suggests that the shifts in risk differences from 8 to 40 weeks may be a reflection of differential withdrawal rather than the treatments themselves. Another limitation is that the studies from which these data were generated were restrictive in terms of patient selection criteria; therefore, data presented here cannot be confidently generalized to all patients with schizophrenia. Finally, there may also be a greater placebo effect with the LAI formulation than with an oral formulation. Mitigation of this limitation would require a direct comparison between treatments along with a placebo arm.

Conclusion
----------

The combination of a comparative approach for multiple endpoints and the BRAT framework enabled meaningful comparisons of benefits and risks between the two different clinical trials. The benefit--risk data suggest an advantage in efficacy for PP1M versus paliperidone ER, with no increase in safety risk in early treatment that may lessen with time. This suggests that benefit exceeds risk for PP1M compared with paliperidone ER when used as maintenance treatment in stable patients with schizophrenia.
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